We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.06 | 2.11% | 51.1755 | 52.16 | 50.71 | 51.54 | 23,013,961 | 01:00:00 |
From Sep 2021 to Sep 2024
By Colin Kellaher
Bristol Myers Squibb Co. has won Food and Drug Administration approval for expanded use of the blockbuster arthritis drug Orencia as the first U.S. drug for the prevention of moderate-to-severe acute graft-versus-host disease.
The agency said the approval covers Orencia in combination with certain immunosuppressants for patients two years of age or older undergoing hematopoietic stem-cell transplantation from an unrelated donor.
Acute graft-versus-host disease is a potentially fatal complication that occurs when donor bone marrow or stem cells attack the graft recipient.
Bristol Myers reported revenue of $2.44 billion for the first nine months of the year for Orencia, which was previously approved in the U.S. to treat adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and adult psoriatic arthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 15, 2021 12:29 ET (17:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
